Email not displaying correctly? View it in your browser
Forward to a colleague | Sign up to BNF eNews
BNF BNF for Children Medicines Complete
April 2018 Share this issue Facebook LinkedIn Twitter
 
I Welcome
Welcome to the April BNF eNewsletter.
Two new drug monographs have been added to the BNF in the last month, tivozanib and ocrelizumab.

This issue includes dose changes for alprostadil, hydroxycarbamide, lacosamide, and papaveretum as well as updated guidance on the management of acute sinusitis, and updated guidance and country recommendations for malaria prophylaxis. We have included updated MHRA advice on contraception for male patients undergoing treatment with mycophenolate mofetil and mycophenolic acid. You will also find NICE technology appraisals for golimumab for treating non-radiographic axial spondyloarthritis, lenvatinib with everolimus for previously treated advanced renal cell carcinoma, and fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer.

See also our latest BNF case study on endometriosis, the symptoms and treatments.
Kind regards,
BNF Team
I In this issue
Significant changes More >  
News More >  
How to purchase BNF More >  
Drug safety update More >  
Feedback More >  
I Significant
changes
This month's changes to the clinical content of these publications are described in three parts:

BNF and BNFC update should be read by all users
BNF update should be read by all users of the BNF
BNFC update should be read by all users of the BNF for Children
BNF 72 - BNFC 2016-2017
BNF Update
Ocrelizumab: new drug monograph
For further information, see ocrelizumab.
Tivozanib: new drug monograph
For further information, see tivozanib.
Daclizumab (Zinbyrta®): suspension and recall for safety reasons; review patients as soon as possible and start alternative therapy (MHRA advice)
For further information, see daclizumab.
Dose changes
Alprostadil [Initial dose for erectile dysfunction and neurogenic erectile dysfunction for Viridal® Duo]
For further information, see alprostadil.
NICE technology appraisal update:
NICE technology appraisals that have been added to the BNF this month include:
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
Golimumab for treating non-radiographic axial spondyloarthritis
Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Ceritinib for untreated ALK-positive non-small-cell lung cancer
Other changes
To review other changes in the BNF, click on changes.
BNF BNF for Children Update
Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients (MHRA advice)
For further information, see mycophenolate mofetil.
Sinusitis (acute): updated guidance on management
For further information, see sinusitis (acute).
Malaria prophylaxis: update to country recommendations and guidance
For further information, see malaria prophylaxis.
Dose changes
Papaveretum [clarification of dosing]
For further information, see papaveretum.
I News
BNF Case study: Endometriosis - symptoms and treatment
Our BNF case study will help improve your understanding of endometriosis and available treatment options.
Reminder - help from CPPE with BNF 74
An interactive PDF e-learning programme from the Centre for Pharmacy Postgraduate Education (CPPE) will help you familiarise yourself with recommendations in BNF 74. It comprises 10 practical case studies that help you keep up to date with recent changes in the BNF, and can be accessed here.
BNF 74
I How to purchase BNF
Purchase Print copies
Purchase print copies
To order the March 2018 edition, visit the Pharmaceutical Press website.
More
Purchase a print subscription
Purchase a print subscription and save money
A print subscription is the best way to ensure access to the latest copy of BNF as soon as it publishes.
More
BNF online
BNF online
Outside the UK, content is available via a subscription to MedicinesComplete.
Email us
BNF eBook
BNF eBook
BNF is also available as a PDF eBook.
More
Drug Safety Update
Drug Safety Update is a monthly newsletter from
the MHRA and Commission on Human Medicine.
Please follow this link to review this month's Drug Safety Update.
I Feedback on our eNewsletter
Please let us know if there are any issues that you'd like us to address in our eNewsletters. We welcome your feedback. If you have any comments or suggestions, please let us know at marketing@rpharms.com.
Subscribe to this eNewsletter here
I Related Products
Medicines Complete BNF Pharmaceutical Press
BNF
Copyright © 2018 BMJ Publishing Group Ltd and the Royal Pharmaceutical Society of Great Britain. All rights reserved. Terms of use.
BNF for Children
Copyright © 2018 BMJ Publishing Group Ltd, the Royal Pharmaceutical Society of Great Britain and RCPCH Publications. All rights reserved. Terms of use.
If you do not wish to receive such mailings in the future please click here to unsubscribe.
Pharmaceutical Press, 66-68 East Smithfield, London, E1W 1AW, United Kingdom.